Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.65 and traded as high as $0.75. Lexicon Pharmaceuticals shares last traded at $0.73, with a volume of 2,479,330 shares trading hands.
Wall Street Analyst Weigh In
A number of brokerages recently commented on LXRX. Leerink Partners reiterated a "market perform" rating and issued a $1.00 price target (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, March 4th. Wall Street Zen initiated coverage on Lexicon Pharmaceuticals in a research note on Monday, April 21st. They set a "sell" rating on the stock. Piper Sandler reduced their price target on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and issued a $4.00 price objective on shares of Lexicon Pharmaceuticals in a report on Tuesday. Finally, Leerink Partnrs downgraded Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $3.67.
View Our Latest Analysis on Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Stock Down 11.7%
The stock has a 50-day moving average of $0.68 and a 200-day moving average of $0.65. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.22 and a quick ratio of 2.22. The firm has a market cap of $296.75 million, a price-to-earnings ratio of -1.61 and a beta of 1.00.
Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last released its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.03. The company had revenue of $1.26 million for the quarter, compared to analyst estimates of $1.26 million. Lexicon Pharmaceuticals had a negative return on equity of 103.16% and a negative net margin of 568.04%. Sell-side analysts predict that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.
Institutional Trading of Lexicon Pharmaceuticals
Several large investors have recently made changes to their positions in LXRX. Wellington Management Group LLP boosted its holdings in shares of Lexicon Pharmaceuticals by 2.1% in the 4th quarter. Wellington Management Group LLP now owns 747,996 shares of the biopharmaceutical company's stock valued at $552,000 after purchasing an additional 15,249 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Lexicon Pharmaceuticals by 34.4% during the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 16,136 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in Lexicon Pharmaceuticals by 60.3% in the fourth quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company's stock valued at $48,000 after buying an additional 24,615 shares in the last quarter. Bank of America Corp DE grew its position in Lexicon Pharmaceuticals by 27.4% in the fourth quarter. Bank of America Corp DE now owns 136,407 shares of the biopharmaceutical company's stock valued at $101,000 after acquiring an additional 29,319 shares during the last quarter. Finally, Invesco Ltd. grew its position in Lexicon Pharmaceuticals by 60.6% in the fourth quarter. Invesco Ltd. now owns 104,494 shares of the biopharmaceutical company's stock valued at $77,000 after acquiring an additional 39,420 shares during the last quarter. Institutional investors and hedge funds own 74.70% of the company's stock.
About Lexicon Pharmaceuticals
(
Get Free Report)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
See Also
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
